Latest On Mersana Therapeutics, Inc (MRSN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-09 15:56 EST | News | Mersana Therapeutics GAAP EPS of -$0.52 misses by $0.09, revenue of $7.8M misses by $10.49M | N/A |  |
| 2023-05-09 15:56 EST | News | Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-09 02:12 EST | News | Mersana Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-05-03 13:13 EST | News | Sutro, Mersana jump after Immunogen data for ovarian cancer therapy | N/A | |
| 2023-04-28 21:49 EST | News | Mersana jumps 18% on rival ImmunoGen's ovarian cancer treatment sales | N/A | |
About Mersana Therapeutics, Inc (MRSN):
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC read more...product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
General
- Name Mersana Therapeutics, Inc
- Symbol MRSN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 110
- Fiscal Year EndDecember
- IPO Date2017-06-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.mersana.com
Valuation
- Price/Sales (Trailing 12 Mt.) 1349.26
- Price/Book (Most Recent Quarter) 5.5
- Enterprise Value Revenue 1227.04
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.62
- Next Year EPS Estimate -$1.76
- Next Quarter EPS Estimate -$0.33
- Operating Margin -10641%
- Return on Assets -29%
- Return on Equity -57%
- Revenue 828000
- Earnings Per Share -$1.12
- Revenue Per Share $0.01
- Gross Profit -66208000
- Quarterly Earnings Growth -73.8%
Highlights
- Market Capitalization 1.25 billion
- EBITDA -35152000
- PE Ratio -1.85
- Analyst Target Price $29.8
- Book Value Per Share $3.31
Share Statistics
- Shares Outstanding 69.04 million
- Shares Float 53.96 million
- % Held by Insiders 125%
- % Held by Institutions 98.25%
- Shares Short 8.79 million
- Shares Short Prior Month 8.49 million
- Short Ratio 9.84
- Short % of Float 16%
- Short % of Shares Outstanding 13%
Technicals
- Beta 2.55
- 52 Week High $29.09
- 52 Week Low $4.12
- 50 Day Moving Average 19.94
- 200 Day Moving Average 21.01
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Mersana Therapeutics, Inc (MRSN) Dividend Calendar:
Mersana Therapeutics, Inc (MRSN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Mersana Therapeutics, Inc (MRSN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Mersana Therapeutics, Inc (MRSN) Chart:
Mersana Therapeutics, Inc (MRSN) News:
Below you will find a list of latest news for Mersana Therapeutics, Inc (MRSN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Mersana Therapeutics, Inc (MRSN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest MRSN Trades:
Mersana Therapeutics, Inc (MRSN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-17 | 8-K (Current report) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-03 | 8-K (Current report) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
Mersana Therapeutics, Inc (MRSN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Mersana Therapeutics, Inc (MRSN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 125%
Institutional Ownership: 9825%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-21 | Timothy B Lowinger | Chief Science & Tech. Officer | Sell | 1,874.00 | 17.50 | 32,795.00 | 16,851.00 | |
| 2020-10-21 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 1,874.00 | 3.51 | 6,577.74 | 18,725.00 | |
| 2020-10-21 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 2,227.00 | 6.16 | 13,718.32 | 19,078.00 | |
| 2020-10-20 | Timothy B Lowinger | Chief Science & Tech. Officer | Sell | 1,875.00 | 16.74 | 31,387.50 | 0.00 | |
| 2020-10-20 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 1,611.00 | 7.43 | 11,969.73 | 1,611.00 | |
| 2020-10-20 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 15,240.00 | 1.40 | 21,336.00 | 16,851.00 | |
| 2020-10-20 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 1,875.00 | 3.51 | 6,581.25 | 1,875.00 | |
| 2020-10-20 | Timothy B Lowinger | Chief Science & Tech. Officer | Buy | 2,227.00 | 6.16 | 13,718.32 | 2,227.00 | |
| 2020-09-21 | Timothy B Lowinger | Chief Science, Tech. Officer | Sell | 12,411.00 | 20.66 | 256,378.99 | 0.00 | |
| 2020-09-21 | Timothy B Lowinger | Chief Science, Tech. Officer | Sell | 3,749.00 | 20.66 | 77,444.59 | 12,411.00 | |
| 2020-09-21 | Timothy B Lowinger | Chief Science, Tech. Officer | Buy | 3,749.00 | 3.51 | 13,158.99 | 16,160.00 | |
| 2020-09-21 | Timothy B Lowinger | Chief Science, Tech. Officer | Buy | 4,454.00 | 6.16 | 27,436.64 | 16,865.00 | |
| 2020-09-14 | Eva M. Jack | Chief Bus. Officer, Tres, Sec. | Sell | 35,248.00 | 22.00 | 775,456.00 | 0.00 | |
| 2020-09-14 | Eva M. Jack | Chief Bus. Officer, Tres, Sec. | Buy | 35,248.00 | 1.53 | 53,929.44 | 35,248.00 | |
| 2020-07-02 | Ashish Mandelia | VP, Controller | Sell | 3,383.00 | 22.49 | 76,083.67 | 0.00 | |
| 2020-06-01 | Lawrence M Alleva | Director | Buy | 700.00 | 22.94 | 16,058.00 | 1,085.00 | |
| 2020-06-01 | Lawrence M Alleva | Director | Buy | 385.00 | 22.97 | 8,843.45 | 385.00 | |
| 2020-04-14 | SCOTT D SANDELL | 10% Share Holder | Sell | 274.00 | 9.22 | 2,526.28 | 0.00 | |
| 2020-04-13 | Anthony A. Jr. Florence | 10% Share Holder | Sell | 20,914.00 | 8.50 | 177,775.27 | 0.00 | |
| 2020-04-13 | FOREST BASKETT | 10% Share Holder | Sell | 20,914.00 | 8.50 | 177,775.27 | 0.00 | |